FDA Approval Alert: The Need-to-Know | Tarlatamab in Extensive-Stage Small Cell Lung Cancer

In May 2024, the FDA granted accelerated approval to tarlatamab-dlle for patients with extensive-stage small cell lung cancer who have progressed on platinum-based chemotherapy.

Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.
Uncovering Subsequent Research Considerations for Tarlatamab in ES-SCLC
Video
Oct 3, 2025 12:00 PM
Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.
The recent accelerated approval of tarlatamab marks a significant milestone in treating relapsed extensive-stage small cell lung cancer (ES-SCLC).
Tarlatamab May Offer New SOC for Relapsed ES-SCLC With Brain Metastases
Video
Oct 2, 2025 12:00 PM
The recent accelerated approval of tarlatamab marks a significant milestone in treating relapsed extensive-stage small cell lung cancer (ES-SCLC).
Tarlatamab has demonstrated superiority to lurbinectedin as a treatment for patients with ES-SCLC who have progressed after frontline chemoimmunotherapy.
Moving Beyond Chemotherapy in Relapsed/Refractory ES-SCLC Treatment
Video
Sep 30, 2025 10:00 PM
Tarlatamab has demonstrated superiority to lurbinectedin as a treatment for patients with ES-SCLC who have progressed after frontline chemoimmunotherapy.
Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.
Exploring T-Cell Engager Use in Chemotherapy-Resistant ES-SCLC
Article
Sep 30, 2025 8:00 PM
Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.
The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.
FDA Approves Tarlatamab After Progression on Chemotherapy in ES-SCLC
Article
May 16, 2024 8:15 PM
The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.